Trusted Source for Health Articles
Trusted Source for Health Articles
Evidence-based coverage of weight loss drugs, GLP-1 science, metabolic health, and fat loss strategies. Includes the latest research on Ozempic, Mounjaro, Wegovy, tirzepatide, and semaglutide — reviewed by Dr. Ajit Kumar, MD (Medicine) | MA Psychology.
Medically Written & Reviewed By Dr. Ajit Kumar, MD (Medicine) — Founder, Medimadad. About the Author | Editorial Policy I get asked about alcohol and Ozempic almost every week in clinic, and I’ve noticed the questions cluster around the same handful of assumptions — most of them half-right, which is actually worse than being wrong, […]
Medically Written & Reviewed By Dr. Ajit Kumar, MD (Medicine) — Founder, Medimadad. About the Author | Editorial Policy Millions of people are taking Ozempic, Wegovy, and Mounjaro with impressive results. But a growing body of research is asking a question that very few people in the weight loss conversation are talking about: why do […]
Medically Written & Reviewed By Dr. Ajit Kumar, MD (Medicine) — Founder, Medimadad. About the Author | Editorial Policy As GLP-1 drugs have dominated health headlines, a provocative question has emerged: if a weekly injection can produce 15-20% body weight loss with minimal effort, is there any point to the gym? Conversely, if someone cannot […]
Medically Written & Reviewed By Dr. Ajit Kumar, MD (Medicine) — Founder, Medimadad. About the Author | Editorial Policy When tirzepatide (Mounjaro/Zepbound) was approved, it was described as a dual GLP-1/GIP receptor agonist. Most of the attention went to GLP-1 – the hormone semaglutide (Ozempic) also targets, and the one that has dominated obesity medicine […]
Medically Written & Reviewed By Dr. Ajit Kumar, MD (Medicine) — Founder, Medimadad. About the Author | Editorial Policy Sleep apnea affects an estimated 100 million people worldwide, and India carries a disproportionate burden – with obesity, anatomical factors, and underdiagnosis creating a perfect storm. The standard treatment, CPAP therapy, is effective but poorly tolerated: […]
Medically Written & Reviewed By Dr. Ajit Kumar, MD (Medicine) — Founder, Medimadad. About the Author | Editorial Policy In August 2023, the New England Journal of Medicine published results that changed cardiovascular medicine. The SELECT trial — the largest randomised trial of a GLP-1 drug in cardiovascular patients, 17,604 people followed for over 3 […]
Medically Written & Reviewed By Dr. Ajit Kumar, MD (Medicine) — Founder, Medimadad. About the Author | Editorial Policy For the first time in obesity medicine, doctors have two genuinely different classes of injectable weight loss drugs to choose from. Semaglutide (Ozempic/Wegovy) targets one hormone receptor; tirzepatide (Mounjaro/Zepbound) targets two, and produces meaningfully greater average […]
Medically Written & Reviewed By Dr. Ajit Kumar, MD (Medicine) — Founder, Medimadad. About the Author | Editorial Policy Millions of people have started semaglutide injections and experienced dramatic weight loss. But what happens when they stop? The answer, backed by rigorous clinical data, is uncomfortable – and it has fundamentally changed how doctors think […]
Medically Written & Reviewed By Dr. Ajit Kumar, MD (Medicine) — Founder, Medimadad. About the Author | Editorial Policy Most patients with kidney disease are told to be cautious with new medications. Yet one of the largest kidney trials ever conducted has just delivered a striking verdict on semaglutide — the drug sold as Ozempic […]
Medically Written & Reviewed By Dr. Ajit Kumar, MD (Medicine) — Founder, Medimadad. About the Author | Editorial Policy Everyone knows Ozempic and Wegovy for one reason: weight loss. But in 2026, a wave of new research is revealing something that is catching even doctors off guard. These GLP-1 receptor agonist drugs are doing far […]
🦺Medically Written & ReviewedBy Dr. Ajit Kumar, MD (Medicine) — Lifetime Member, Indian Medical Association. About the Author | Editorial Policy Weight loss surgery dominated obesity treatment for over two decades. Surgeons could not keep up with demand. Hospital waiting lists stretched months long. Then, almost overnight, the operating rooms started getting quieter. The reason […]
Medically Written & Reviewed By Dr. Ajit Kumar, MD (Medicine) — Founder, Medimadad. About the Author | Editorial Policy For millions of people managing type 2 diabetes or considering GLP-1 therapy for weight loss, injections have always been the biggest barrier. That barrier may now be coming down. Novo Nordisk has launched an oral version […]
